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Abstract Proteolysis is the general term to describe the
process of protein degradation into peptides. Proteasomes
are the main actors in cellular proteolysis, and their activity
can be measured in in vitro digestion experiments. However,
in vivo proteolysis can be different than what is measured
in these experiments if other proteases participate or if pro-
teasomal activity is different in vivo. The in vivo proteolysis
can be measured only indirectly, by the analysis of peptides
presented on MHC-I molecules. MHC-I presented peptides
are protected from further degradation, thus enabling an
indirect view on the underlying in vivo proteolysis. The
ligands presented on different MHC-I molecules enable dif-
ferent views on this process; in combination, they might
give a complete picture. Based on in vitro proteasome-
only digestions and MHC-I ligand data, different proteolysis
predictors have been developed. With new in vitro diges-
tion and MHC-I ligand data sets, we benchmarked how
well these predictors capture in vitro proteasome-only activ-
ity and in vivo whole-cell proteolysis, respectively. Even
though the in vitro proteasome digestion patterns were best
captured by methods trained on such data (ProteaSMM
and NetChop 20S), the in vivo whole-cell proteolysis was
best predicted by a method trained on MHC-I ligand data
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(NetChop Cterm). Follow-up analysis showed that the likely
source of this difference is the activity from proteases other
than the proteasome, such as TPPII. This non-proteasomal
in vivo activity is captured by NetChop Cterm and should
be taken into account in MHC-I ligand predictions.
Keywords Proteasomal cleavage · Proteolysis ·
MHC-I presentation · Peptide processing
Introduction
The proteasome degrades intracellular proteins, marked for
degradation by the ubiquitination pathway (Hershko and
Ciechanover 1992). Protein degradation, i.e., proteolysis, is
important to remove miss-folded proteins, to regulate cel-
lular processes such as the cell-cycle or for the production
of MHC-I ligands (Goldberg 2003; Seifert et al. 2010;
van Leuken et al. 2008; Clijsters et al. 2013; Kloetzel
2001). Peptide fragments that result from proteolysis are
rapidly degraded by cytosolic aminopeptidases (Reits et al.
2003). However, few peptides escape this degradation and
are transported to the endoplasmatic reticulum (ER) by
the transporter associated with antigen processing (TAP),
where they can form peptide-MHC-I complexes (pMHCs)
(Neefjes et al. 2011). pMHCs are presented on the cell
surface to enable immune surveillance by T cells.
Most cells express the constitutive proteasome, which is
a barrel-shaped multi-subunit protein complex, composed
of two α- and two β-rings, where each ring contains seven
subunits. In the β ring of the constitutive proteasome, three
proteins are present that have proteolytic capacity: β1, β2,
and β5 (Kloetzel and Ossendorp 2004). Under the influence
of interferon-γ (IFNγ ), these subunits can be substituted
by β1i , β2i , and β5i , respectively, to form the so-called
86 Immunogenetics (2015) 67:85–93
immunoproteasome (Aki et al. 1994). Whereas the consti-
tutive proteasome has a preference to cleave hydrophobic,
acidic, and basic amino acids, the immunoproteasome is
more efficiently cleaving after hydrophobic and basic amino
acids (Gaczynska et al. 1993; Toes et al. 2001; Kesmir et al.
2003). Other proteasome types can be formed by a com-
bination of constitutive and immunoproteasomal subunits
(Guillaume et al. 2010), or with the β5t subunit that is only
expressed in cortical thymic epithelial cells (Murata et al.
2007). These different proteasome types largely over-
lap in their cleavage preferences (Guillaume et al. 2010;
Murata et al. 2007; Florea et al. 2010), though the effi-
ciency can differ at different cleavage sites which has an
influence on the repertoire of MHC-I presented peptides
(Kincaid et al. 2012).
Two main approaches have been taken to study prote-
olytic activity: in vitro digestion experiments and in vivo
MHC-I-ligand elutions. In an in vitro digestion experi-
ment, a protein is incubated with proteasomes. The pep-
tide fragments that are formed during the digestion can
be detected by mass spectrometry, and cleavage sites can
be inferred from the fragments (Emmerich et al. 2000;
Tenzer et al. 2004; Toes et al. 2001). So far, the cleav-
age sites of only three proteins, i.e., β-casein, enolase, and
prion protein, have been determined in such in vitro assays
(Emmerich et al. 2000; Tenzer et al. 2004; Toes et al. 2001).
Alternatively, in vivo proteolytic activity can be measured
by the analysis of digestion fragments that form pMHCs;
these fragments can be eluted from a cell and identified by
mass spectrometry. The C-terminus of the MHC-I presented
peptide is generated by proteolytic activity and reflects an
in vivo cleavage site in the protein from which the MHC-
I ligand was derived (Kloetzel 2001). However, as many
cleavage sites will result in fragments that do not become
MHC-I ligands, only a small subset of all cleavage sites
can be detected via this approach. In addition, other pep-
tidases such as ACE, TPPII, and Nardilysin (Geier et al.
1999; Shen et al. 2008; Kessler et al. 2011) can influence
the C-terminus of MHC-I ligands. Therefore, the MHC-I-
ligand data is more likely to reflect the proteolytic activity
of all cellular proteases, rather than the activity of just the
proteasomes or one proteasome-type.
To study proteolyis and to aid MHC-I ligand predic-
tions, different proteolyis predictors have been developed
(Holzhutter et al. 1999; Holzhutter and Kloetzel 2000;
Kesmir et al. 2002; Nielsen et al. 2005; Tenzer et al. 2005;
Ginodi et al. 2008; Kuttler et al. 2000; Nussbaum et al. 2001.
Most predictors, e.g., FragPredict (Holzhutter et al. 1999;
Holzhutter and Kloetzel 2000), ProteaSMM (Tenzer et al.
2005), PAProC (Kuttler et al. 2000; Nussbaum et al. 2001),
and PepCleave (Ginodi et al. 2008), have been trained on the
in vitro proteasome digestion data from β-casein and eno-
lase (Emmerich et al. 2000; Toes et al. 2001). NetChop 20S
(Kesmir et al. 2002; Nielsen et al. 2005) and the so-called
enhanced versions of ProteaSMM are trained on the in
vitro proteasome digestion data from β-casein, enolase, and
the prion-protein (Emmerich et al. 2000; Toes et al. 2001;
Tenzer et al. 2004). Unlike the other predictors, NetChop
Cterm is trained on in vivo MHC-I ligand data (Kesmir et al.
2002; Nielsen et al. 2005). Besides the different data sets
that were used for training the methods, different compu-
tational techniques were used to construct the predictors.
For instance, ProteaSMM models the cleavage pattern with
a stabilized matrix method (SMM) using six amino acids
C-terminal and four amino acids N-terminal of a potential
cleavage site, and NetChop is based on a neural network
that uses nine amino acids C-terminal and eight amino acids
N-terminal of a potential cleavage site.
In 2005, Tenzer et al. (2005) bench-marked FragPredict,
PAProC, NetChop-2.0, and ProteaSMM on several data sets,
and showed that ProteaSMM best predicted in vitro pro-
teasome digestion cleavage patterns, whereas NetChop-2.0
Cterm best predicted the cleavage patterns based on MHC-
I ligands. Tenzer et al. (2005) argued that the increased
performance of NetChop-2.0 Cterm on the MHC-I ligand
data was due to a recognition of TAP-transportable pep-
tides. After this study, NetChop was updated to version 3.0
(Nielsen et al. 2005) and a new method, PepCleave, was
developed (Ginodi et al. 2008). Unfortunately, PepCleave
cannot be compared to the other predictors as it predicts
fragments and not cleavages (Ginodi et al. 2008). Therefore,
we have chosen to compare ProteaSMM and the newest ver-
sion of NetChop on new in vitro proteasome digestion data
sets, and a new benchmark set of MHC-I ligands. Next to
benchmarking, our analysis shines light on the nature of
the difference between in vitro proteasome-only and in vivo
whole-cell proteolytic activities, suggesting an important
role for proteases other than the proteasome.
Results
Predicting in vitro cleavage patterns
To compare proteasome predictors, we generated a new
independent data set. This data set was based on in vitro
digestions of 17–30 amino acids long HIV–1 peptides; the
products of these digestions were analyzed using mass
spectrometry to determine cleavage and non-cleavage sites
(see “Methods” section). Digestions were performed with
either constitutive or immunoproteasomes. Of 368 possible
cleavage sites, 150 (41 %) were used by the constitutive pro-
teasomes, and 148 by the immunoproteasomes, 103 sites (of
the 148 cleavage sites) were cleaved by both proteasome-
types (Supplementary Table S1). Thus, even though the dif-
ferent proteasomes can target the different sites with varying
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efficiencies, the set of cleavage sites that is identified in this
assay largely overlaps.
The prediction performance of ProteaSMM and
NetChop-3.0 was analyzed using receiver operator charac-
teristic (ROC) curves, where the number of correct and false
predictions is plotted for every prediction threshold (Swets
1988). The area under a ROC-curve (AUC) is a perfor-
mance measure of the predictor, and is widely used because
it is threshold independent (Swets 1988). For each predictor
(and different versions of the predictors), the AUCs were
determined on both constitutive and immunoproteasomal
cleavage patterns obtained from the in vitro digestions
(Table 1). In general, the methods performed better in
predicting the immunoproteasomal cleavage pattern. This
could be explained by the more biased cleavage preference
of immunoproteasomes, that cleave after hydrophobic and
basic amino acids with greater, and after acidic amino acids
with lesser efficiency (Gaczynska et al. 1993; Toes et al.
2001; Kesmir et al. 2003). Such a more biased cleavage
pattern might be easier to predict. The immunoproteasomal
cleavage pattern was best predicted by proteaSMM-
immuno and proteaSMM-constitutive (ROC-comparison
test: p < 0.001; Table 1), and the constitutive cleavage
pattern was best captured by proteaSMM-constitutive
and NetChop-3.0 20S (ROC-comparison test: p < 0.001;
Table 1). Surprisingly, the enhanced ProteaSMM ver-
sions did not perform better, even though they are trained
on extra data from proteasomally digested prion protein
(Tenzer et al. 2004). NetChop-3.0 20S is also trained on
prion data, but no version of this method is available that
is not trained on prion data, to test if prion data negatively
affects the performance of NetChop-3.0 20S.
In summary, the methods that have been trained on
in vitro proteasome digestion data (proteaSMMs and
NetChop-3.0 20S) outperformed the method that has been
trained on in vivo MHC-I ligand data (NetChop-3.0 Cterm),
which agrees with previous observations (Tenzer et al. 2005;
Saxova et al. 2003) and the expectation that methods trained
on in vitro data can best predict proteasome-only cleavage
patterns.
Predicting in vivo cleavage patterns
In vivo proteolytic activity can be rather different from pure
proteasomal activity, if other peptidases e.g., ACE, TPPII,
or Nardilysin (Geier et al. 1999; Shen et al. 2008, 2011;
Kessler et al. 2011) contribute to the in vivo proteolysis. As
a result, the ability of different proteasome predictors to pre-
dict in vivo proteolysis might be different from their ability
to predict in vitro proteasome-only cleavages. To test and
compare the in vivo proteolysis prediction performances, we
inferred in vivo cleavage sites from non-redundant MHC-
I ligands that have been identified from 2005 on, after
NetChop Cterm was last updated (n = 832; see Fig. 1 and
“Methods” section). A data set of in vivo non-cleavage
sites was derived in two ways: (1) by shuffling, 100 non-
cleavage sites were made by shuffling the 19 amino acids
flanking a cleavage site (the area used by NetChop for pre-
dictions plus one N-terminal and one C-terminal extension,
see Fig. 2). (2) By assuming that all sites in the source
protein of the MHC-I ligand that are not identified as cleav-
age sites are non-cleavage sites (“Methods” section). The
predictors were assessed for their capacity to discriminate
cleavage sites from non-cleavage sites, by comparing AUC
values. Not surprisingly, NetChop-3.0 Cterm most accu-
rately captured the in vivo cleavage pattern irrespective of
the non-cleavage data set (ROC-comparison test: p < 0.001;
Fig. 3). This is expected as NetChop Cterm has been trained
on in vivo cleavage patterns inferred from MHC-I ligands.
As in vivo proteolysis is inferred from MHC-I lig-
and data and NetChop Cterm is trained on such data,
Tenzer et al. (2005) noted in an earlier benchmark study
that the superior performance of NetChop might be due
to a biased recognition of peptides with a high TAP affin-
ity. To exclude this effect, the performance of the different
proteasome predictors was tested in combination with a
Table 1 Predictor performances on in vitro proteasomal cleavage pattern predictions
Constitutive cleavage Immunoproteasomal cleavage
Predictor prediction (AUC) prediction (AUC)
NetChop–3.0 Cterm 0.671 0.731
NetChop–3.0 20S 0.713 0.748
ProteaSMM immuno 0.685 0.803
ProteaSMM immuno enhanced 0.650 0.767
ProteaSMM constitutive 0.702 0.792
ProteaSMM constitutive enhanced 0.656 0.776
The prediction performance was determined for constitutive and immunoproteasomal cleavage patterns (second and third column, respectively),
as AUC of ROC-curves. In boldface the predictors are indicated that performed better than the other predictors (ROC-comparison test: p< 0.001).
These predictors were not significantly different in their performance (ROC-comparison test: p> 0.001)
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Fig. 1 Constructing the MHC-I ligand data set. MHC-I ligands and
source proteins, that were discovered in elution studies, were derived
from the SYFPHEITI database (Rammensee et al. 1999) and the IEDB
database (Vita et al. 2010). The data sets were combined and non-
redundant ligands that were not published before 2005 were selected.
Every MHC-I ligand in its source protein represents a cleavage site;
non-cleavage sites were derived by either shuffling an area of 19 amino
acids around the cleavage site (Fig. 2 and “Methods” section), or by
defining all other sites in the source proteins of MHC-I ligands as
non-cleavage sites (“Methods” section)
TAP transport predictor (Peters et al. 2003). Therefore, we
first followed the approach from Tenzer et al. (2005) by
summing TAP-transport and proteasome cleavage scores
Fig. 2 Constructing non-cleavage sites by shuffling. The C-terminus
of an MHC-I ligand (between P1’ and P1) is defined as a cleavage site.
An area of 19 amino acids (from P10’ to P9) around a cleavage site was
shuffled and the middle position was assigned as a non-cleavage site.
For every cleavage site, 100 non-cleavage sites were constructed. The
positions that are used by NetChop-3.0 (P9’ to P8) and ProteaSMM
(P6’ to P4) for predicting cleavage probabilities are indicated
into a single score. For both non-cleavage site definitions,
NetChop-3.0 Cterm outperformed the other predictors, even
when the TAP transport scores were differently weighted
prior to summation (Fig. 4 and S1).
In an AUC-analysis, one can test the predictive perfor-
mance of a single set of scores. However, we wanted to
test the performance of a combination of two scores, i.e.,
proteasome cleavage and TAP transport scores, as an alter-
native to the additive model proposed by as Tenzer et al.
did. Therefore, we developed a new method to measure
the performance of these two scores simultaneously. In this
method, for every TAP binding threshold, the performance
of the cleavage predictor was measured on cleavage and
non-cleavage sites exceeding the threshold. Next, an inte-
gration over all the performance scores was combined in a
score called volume under the plane (VUP; see “Methods”
section). For both non-cleavage definitions, NetChop-3.0
Cterm outperformed the other proteasome predictors based
on VUP-scores (ROC-comparison test: p < 0.001; Fig. 3),
again indicating that its higher performance is not due to a
biased recognition of TAP ligands. Taken together, NetChop
Cterm seems to predict in vivo proteolysis better than the
other predictors that are trained on proteasome-only in vitro
proteolysis data. This suggests that the proteolytic activity
in vivo that underlies MHC-I ligand production is markedly
different from in vitro proteasome-only proteolysis.
Comparing in vitro and in vivo proteolysis activity
To better understand why NetChop-3.0 Cterm predicts in
vivo proteolysis better than the other predictors, even though
these predictors better predict proteasome-only in vitro pro-
teolysis, we examined for each predictor which cleavage
sites were given a low prediction score. The cleavage sites
with a bottom 5 % prediction score were selected for fur-
ther analysis. A striking difference between NetChop-3.0
Cterm and the other predictors was observed at position P1’
of these poorly predicted cleavage sites (i.e., the C-terminus
of the MHC-I ligand; Fig. 2). Whereas the amino acids
at position P1’ were equally distributed for NetChop-3.0
Cterm, a Lysine was found in at least 50 % of the cases for
the other predictors (Fig. 5). In other words, the predictors
based on in vitro proteasomal cleavage data fail to capture
the in vivo cleavage after Lysine residues. This fits with the
described proteolytic preferences of TPPII and Nardilysin
(Geier et al. 1999; Kessler et al. 2011), and the suggested
role of these proteases in the generation of MHC-I ligands,
for instance for HLA-A*03 and HLA-A*11 (Seifert et al.
2003; Kloetzel 2004; Kloetzel and Ossendorp 2004. In
addition, other proteases such as ACE have been shown
to influence the generation of MHC-I ligands (Shen et
al. 2008, 2011) and their proteolytic activity could be cap-
tured by NetChop-3.0 Cterm. Taken together, these results
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Fig. 3 Predicting in vivo proteolysis. Proteasome cleavage predictors
were tested as a stand-alone predictor, or in combination with a TAP
predictor, and performance was assessed using AUC and VUP, respec-
tively (see “Methods” section). The performance was tested using
either non-cleavage data sets derived by the shuffling method (a) or
by taking other sites from the source protein as non-cleavage sites (b)
(see Fig. 1 and “Methods” section). Examples of the AUC and the
VUP analyses are shown in the upper part, AUC and VUP scores are
given in the lower part. In all analyses, NetChop-3.0 Cterm showed
the highest performance (ROC-comparison test: p< 0.001). The per-
formance of NetChop-3.0 Cterm is shown in red lines, NetChop-3.0
20S in black, ProteaSMM Immuno in yellow, ProteaSMM Immuno
enhanced in green, ProteaSMM constitutive in blue, and ProteaSMM
constitutive enhanced in magenta lines
suggest that NetChop-3.0 Cterm incorporates the activity of
all different proteases that make a substantial contribution to
in vivo proteolysis, thereby can predict in vivo proteolysis
better.
Discussion
In this study, we analyzed how well different methods can
predict the cleavage patterns in proteolysis. In vitro cleavage
patterns were shown to be best captured by methods trained
on in vitro proteasome digestion data, i.e., ProteaSMM and
NetChop-3.0 20S (Table 1). Similarly, in vivo proteolysis
was best predicted by the method that is trained on MHC-I
ligand data, NetChop-3.0 Cterm (Fig. 3). Furthermore, we
showed that the better prediction of in vivo proteolysis was
not due to an embedded recognition of TAP transportable
peptides (Figs. 3 and 4).
There can be two explanations for the difference between
in vitro and in vivo proteolysis: First, the proteolytic activity
of proteasomes in vitro might be different from their in vivo
activity. This difference might result from the interactions
with other molecules such as PA28 or the 19S cap regula-
tory particle (de Graaf et al. 2011; Emmerich et al. 2000).
Second, other proteases such as TPPII, ACE, or Nardilysin
might make a substantial contribution to the in vivo
proteolysis (Geier et al. 1999; Shen et al. 2008, 2011;
Kessler et al. 2011). The best described example of in
vivo proteolytic activity that is not observed in vitro is the
cleavage after Lysine residues. This activity is required to
generate ligands for HLA–A*03 and HLA–A*11 that bind
peptides with a Lysine at the C-terminus (Seifert et al. 2003;
Kloetzel 2004; Kloetzel and Ossendorp 2004). A well-
described example of such peptides is the HIV Nef-derived
epitope at positions 73 to 82 with a Lysine at its C-terminus,
and it was shown that the generation of this peptide depends
on TPPII activity (Seifert et al. 2003). However, it is not yet
known how dominant this endopeptidase activity is within
the TPPII enzyme complex (Geier et al. 1999), and there-
fore it is not yet clear whether TPPII is responsible for
all the activities creating the peptides with a Lysine at its
C-terminal. More recently, a more detailed analysis of the
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Fig. 4 Predicting in vivo proteolysis by combining proteolysis and
TAP transport predictor scores. For the different proteasome cleavage
predictors, the proteasome cleavage prediction score was added to the
TAP transport prediction score (as proposed by Tenzer et al. (2005)).
Prediction performance was measured as the AUC of an ROC-curve
(Y-axis), using the shuffled sequences as non-cleavage sites (see Fig. 2
and “Methods” section). When combining the scores, the weight of the
TAP transport score was changed by the factor W (on the X-axis). The
combined score (C), based on the TAP transport (T ) and proteolysis
(P ) score would be C = W ∗ T + P . As a result, the proteasome
cleavage or the TAP transport predictor has a larger influence in the
combined score if W is smaller or larger, respectively. See Fig. 3 for
color coding
substrate specificity of TPPII has been published , which
suggests that the endopeptidase activity of TPPII is very
much dependent on the length of the substrate and thus is
not likely to be a very general enzymatic activity of TPPII.
We show that only NetChop-3.0 Cterm captures this hall-
mark of in vivo proteolysis (Fig. 5). As this activity has
not been contributed to the proteasome, we conclude that
NetChop Cterm has learned to incorporate non-proteasomal
proteolytic activity.
A biased recognition of TAP transportable peptide is not
explaining the increased performance of NetChop Cterm on
the prediction of in vivo cleavage sites derived from MHC-
I ligand data (Figs. 4 and 5). Similarly, one could think
that a bias to recognize MHC-I presented ligands should be
controlled. NetChop Cterm, was trained on in vivo cleav-
age sites derived from a set of pMHCs with a homogenous
distribution of MHC-I molecules with various binding pref-
erences (Nielsen et al. 2005) to minimize such a bias that
would be due to the recognition of MHC-I binding peptides.
In addition, the in vivo cleavage/non-cleavage site data sets
in this study are derived from peptides that were not used
to train NetChop Cterm and that were eluted from many
different MHC-I molecules.
The evaluation of different proteasome cleavage predic-
tors depends on the construction of a set of non-cleavage
Fig. 5 Proteolytic activity after Lysine residues is only predicted by
NetChop-3.0 Cterm. For every proteasome cleavage predictor, 5 % of
the true cleavage sites with the lowest prediction scores were deter-
mined. The amino acid profile at P1’ (i.e., the C-terminus of the
presented MHC-I ligand) of these cleavage sites with a low prediction
score was analyzed. The height of the letters represents their frequency
in the amino acid profile
sites, as the performance on these and on the true cleav-
age sites needs to be compared. Unfortunately, a substan-
tial set of true non-cleavage sites is not available, and
therefore we have to rely on assumptions when compil-
ing a set of non-cleavage sites. To prevent a bias as a
result of such assumptions, we have followed two differ-
ent sets of assumptions when constructing the non-cleavage
sites. First, non-cleavage sites were made by shuffling the
sequence around a cleavage site to destroy any motif that is
used by the proteasome while keeping the same distribution
of amino acids. Second, we considered other positions in
the source protein as non-cleavage sites. Although identical
conclusions were drawn from the analyses with the different
sets non-cleavage sites, identification of true in vivo non-
cleavage sites is required to permanently settle this issue or
to describe sequence motifs that truly inhibit proteasomal
cleavage.
The development of proteasome predictors serves two
goals. First, to understand the specificity and biochemical
processes that underly proteolysis. Second, to predict and
understand how this process influences the MHC-I ligan-
dome. With respect to the first goal, we show that profound
differences between proteasome activity in vitro and cel-
lular proteolysis in vivo exist, suggesting a non-negligible
role of non-proteasomal proteases. Evidently, the specificity
of these additional proteases should be taken into account
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for optimal MHC-I ligand predictions. Therefore, we con-
clude that NetChop Cterm or future proteolysis predictors




Proteasomal in vitro cleavage patterns were derived from a
digestion of HIV-1 peptides with constitutive or immuno-
proteasomes, as explained in (Peters et al. 2002). Sixteen
peptides from the HIV-1 proteins GAG and TAT, with a
length of 17 to 30 amino acids, were degraded. After 0,
1, 2, 4, 8, and 24 h of degradation, peptide fragments
were analyzed using mass spectrometry (as in Peters et al.
(2002)). To avoid analyzing secondary cleavage products,
peptide fragments found after 4 h of degradation were used
to infer cleavage sites. Of 368 possible cleavage sites, 150
were efficiently cleaved by the immunoproteasome after 4 h
and 148 were efficiently cleaved by the constitutive protea-
some; 103 sites (69 %) were shown to be cleaved by both
proteasome subtypes (Supplementary Table S1). The Pro-
teaSMM proteasome cleavage predictors require six amino
acids N-terminal and four amino acids C-terminal of a pos-
sible cleavage site. Therefore, cleavage predictions cannot
be made at the beginning and end of a peptide sequence.
As a result of this limitation, only 240 (of the 368) sites
could be used to compare the different proteasome predic-
tions. Of these 240 sites, 99 were efficiently cleaved by the
immunoproteasome and 99 were efficiently cleaved by the
constitutive proteasome; 68 sites were put in both sets.
In vivo cleavage sites were inferred from MHC-I lig-
and data. Ligands that were identified in MHC-I elution
studies were downloaded from the SYFPHEITI database
(Rammensee et al. 1999) and the IEDB database (Vita et al.
2010). Source proteins of the MHC-I ligands were down-
loaded from the NCBI via links that were provided by the
SYFPHEITI and IEDB databases. The C-terminal residue
of an MHC-I ligand was regarded as position P1’ of a
cleavage site (Fig. 2). In total, 3076 MHC-I ligands with
their source protein were derived from the SYFPHEITI
database and 457 MHC-I ligands with their source protein
were derived from the IEDB database. Identical peptides,
or peptides that were either a C- or N-terminal extension
of each other, were regarded as redundant. In addition, the
ligands and their corresponding source proteins that were
published before 2005, or which were redundant/identical
to an MHC-I ligand published before 2005, were excluded
because they could have been used for training of NetChop-
3.0 Cterm. This filtering resulted in 832 MHC-ligands
and their source proteins, of which every MHC-I ligand
corresponds to a peptide fragment that is generated by in
vivo proteolytic activity (Fig. 1).
Detecting in vivo non-cleavage sites based on the
absence of a peptide in the MHC-I ligand databases is
not possible, as many other reasons might underlie the
absence of an MHC-I ligand, e.g., further degradation of the
fragment or low affinity to MHC-I molecules. Therefore,
non-cleavage sites were generated in two ways: (1) by shuf-
fling of an area of 19 amino acids around the cleavage site
(the longest flanking region used by a proteasome predictor
method plus one extra amino acid on each side, as indicated
in Fig. 2). After shuffling, the middle position, previously
corresponding to the cleavage site, was assigned as a non-
cleavage site. For every cleavage site, 100 non-cleavage
sites were generated, i.e., in total 83.200 non-cleavages sites
(Fig. 1). The advantage of this method is that the amino
acid frequencies of cleavage and non-cleavage sites remain
identical. (2) All sites in the source proteins of the MHC-I
ligands, that were not assigned as a cleavage site were
assumed to be non-cleavage sites (N = 507.538, Fig. 1).
Prediction performance measures
Proteasome cleavage and TAP transport predictions were
performed as suggested by the developers of the different
prediction methods (Peters et al. 2003; Tenzer et al. 2005;
Nielsen et al. 2005). The different proteasome predictors
were assessed for their performance in discriminating cleav-
age from non-cleavage sites. First, the performance of the
proteasome predictors was tested using receiver operator
characteristic (ROC) curves (Swets 1988). In a ROC curve,
true positive proportions (TPP) and false positive predic-
tions (FPP) are plotted on the y- and x-axis, respectively,
for every threshold. The area under the ROC curve (AUC)
is a measure of the predictor’s performance. If a predictor
performs well, the TPPs increase faster than the FPP, and
the AUC becomes larger than 0.5; the maximal AUC is 1.0.
The AUC can only be determined on a single set
of prediction scores. However, we aimed to compare
the prediction performance of the proteasome predic-
tors in combination with the TAP transport predictor.
Therefore, we developed an alternative performance mea-
sure: for every TAP transport prediction value, based
on the cleavage and non-cleavage sites that exceeded
the TAP transport value (T ), the AUC was determined
(AUCT ). If less than 25 cleavage sites or non-cleavage
sites exceeded the TAP threshold, it was discarded. A
score was derived by integrating over all the AUCs
with respect to the TAP threshold values and subse-
quent normalization by the range of TAP thresholds (1).
The resulting score ranges between 0 and 1, a ran-
dom predictor would score 0.5 and a perfect predictor
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would score 1, similar to the scores obtained in an AUC
analysis. This score reflects the predictive performance
of the proteolysis predictor for different data sets which
have been selected over a range of possible TAP val-




i=1 (Ti−1 − Ti) × AUCTi−1 +
(Ti−1−Ti )×(AUCTi−1 −AUCTi )
2
Max(T ) − Min(T )
(1)
Statistics
Statistical tests were performed using the stats-package
from the scipy-module in Python. The difference between
AUC/VUP performance measures was determined by deriv-
ing AUCs/VUPs on 50 new data sets that were gener-
ated by bootstrapping the original data set. The derived
AUCs/VUPs were compared using a paired two-tailed t
test; p values less than 0.001 were considered significant
(as in Tenzer et al. (2005)). We refer to this test as the
ROC-comparison test.
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